NDC product
Remifentanil Hydrochloride
NDC 63323-723 · Fresenius Kabi USA, LLC
Key facts
| Product NDC | 63323-723 |
|---|---|
| Proprietary name | Remifentanil Hydrochloride |
| Nonproprietary name | Remifentanil Hydrochloride |
| Substances | REMIFENTANIL HYDROCHLORIDE |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAVENOUS |
| Labeler | Fresenius Kabi USA, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA206223 |
| DEA schedule | CII |
| Pharmacologic classes | Full Opioid Agonists [MoA], Opioid Agonist [EPC] |
| Marketing start | Jan 19, 2018 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: